Pierpaolo Guzzo to replace Chris Tanner as Chief Financial Officer
Lainate, Italy – December 23, 2020 – Cassiopea SpA (SIX: SKIN), today announced that Chris Tanner is retiring as Chief Financial Officer as of December 31, 2020. Chris Tanner served as Cassiopea’s Chief Financial Officer since its formation and helped bring the Company public in 2015. At the meeting of December 22, 2020, the board approved the nomination of Pierpaolo Guzzo as Chief Financial Officer of Cassiopea starting January 1, 2021. Pierpaolo Guzzo is a Certified Public Accountant, with an extensive track record in accounting, private equity and merchant banking; he will retain his role as board member of Cassiopea.
Diana Harbort, CEO of Cassiopea, said: “We will be forever thankful for the great job that Chris has done as CFO of Cassiopea since the IPO back in 2015 and we wish him much success in his non-executive endeavours”.
Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. Once approved, the Company plans to determine the optimal way of commercializing the products directly in the U.S. and partner the products for countries outside of the US. For further information on Cassiopea, please visit www.cassiopea.com.
Full-year results 2020 March 25, 2021
Shareholders meeting April 29, 2021
Contact for Investors:
Dr. Chris Tanner, CFO & Head of Investor Relations
Tel: +39 02 868 91 124
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.